How industry‑written “consumer protection” bills create the appearance of regulation
while leaving every real public‑health risk untouched.
Kratom Consumer Protection Acts sound reasonable: age limits, labeling, purity standards. But these provisions are a carefully built façade. They regulate the packaging of kratom, not its pharmacology. They treat an unapproved psychoactive substance like a sack of potatoes.
The underlying assumption — that kratom can be made “safe” through retail rules — is pharmacologically unsupported.
New York lawmakers passed a KCPA congratulating themselves for “protecting consumers.” But New York already has a Food, Drug, and Cosmetic Act (Agriculture & Markets Law Article 17) that deems food adulterated if it “bears or contains any added poisonous or deleterious substance which may render it injurious to health.” The FDA has repeatedly stated that kratom products meet this standard. The legislature did not amend or override this existing law — they simply ignored it. The result: kratom can now be legally sold under the KCPA while still technically being illegal to sell as food under state law. That is not clarity; it is legal incoherence.
Notably, the only pharmacist in the legislature, John T. McDonald III, voted for the bill. A pharmacist is trained to understand adulteration and safety standards. His vote suggests not ignorance, but a choice to prioritize retail regulation over enforcement of existing public health law.
Read the full New York analysis →
Wyoming’s proposed KCPA fusses over packaging, bans candy shapes, sets age limits, and caps alkaloid percentages. It does not, however, require the one thing that would actually inform consumers: a plain warning that the product has opioid-like effects and can cause dependence and withdrawal. The bill uses lawyerly language like “may be habit forming” — an evasion, not a warning.
The 2% cap on 7-hydroxymitragynine sounds reassuring, but people do not dose by chemistry charts; they dose by effect. Dependence does not read statutes. This bill keeps kratom on shelves, lets retailers claim it’s “regulated,” and avoids telling consumers the worst risk. It protects lawmakers from having to say the hard thing out loud.
KCPA‑compliant labels disclose ingredients — but not that the product causes opioid‑like dependence. No warning that mitragynine converts in the body to 7‑hydroxymitragynine, a potent μ‑opioid agonist. No mention of withdrawal symptoms: agitation, nausea, insomnia, muscle pain. Consumers see “natural ingredient” and assume safety. The label is a marketing tool, not a health warning.
KCPAs pretend that if the package says “mitragynine 1%,” the consumer can dose safely. In reality, alkaloid content varies wildly between batches. Users chase effects, build tolerance, increase intake — and the law does nothing to stop it. No medical supervision, no titration, no limit on cumulative consumption.
Mitragynine is a prodrug. Its active metabolite, 7‑hydroxymitragynine, is formed inside the user’s body at rates that vary by individual. No label can predict how much opioid activity a person will actually experience. KCPAs ignore this completely.
No KCPA requires manufacturers to report adverse events. No state tracks whether hospitalizations rise or fall after the law passes. Lawmakers celebrate “regulation” while having no data on whether it helps, hurts, or does nothing.
Kratom has no FDA‑approved pathway. It is not a lawful dietary ingredient. States that pass KCPAs are stepping into a vacuum, but they lack the tools of federal drug regulation — clinical trials, prescription controls, post‑market surveillance.
🔍 “Regulation without outcome measurement is theater. KCPAs are the curtain, and the public is the audience — still exposed to every risk the industry promised to fix.”
This critique is drawn from Mothers Against Herbal Abuse’s detailed policy briefs. They examine why KCPAs, by design, cannot resolve the core public‑health threats of unregulated kratom sales.